Effect of Different Dosage of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients With ESLD
Efficacy and Safety of Different Dosage of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients With End-stage Liver Diseases
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Xingshun Qi, MD
- Phone Number: 18909881019
- Email: xingshunqi@126.com
Study Contact Backup
- Name: Mengfan Ruan, MM
- Phone Number: 18226386921
- Email: ruanmengfan1021@163.com
Study Locations
-
-
Liaoning
-
Shenyang, Liaoning, China, 110840
- General Hospital of Northern Theater Command
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18-80 years old
- End-stage liver disease
- Sign informed consent
Exclusion Criteria:
- Tumours of the liver or other organs
- Liver transplantation recipients
- Acute myocardial infarction, acute heart failure, type I and type II respiratory failure, pulmonary embolism, acute cerebral infarction, acute cerebral haemorrhage and other serious cardiopulmonary diseases
- Other diseases that may seriously affect the survival
- Human immunodeficiency syndrome
- Interferon or glucocorticoid therapy within 1 year
- Treated for mental illness
- Participation in other clinical trials within 30 days
- Pregnant or breastfeeding subjects
- Allergic asthma, allergic urticaria, eczema, or a history of multiple drug and food allergies
- Other circumstances that are unsuitable for participation in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: low-dose stem cell group (1×10^6cells/kg per infusion)
Peripheral intravenous infusion of low-dose stem cells
|
Different dosage of umbilical cord-mesenchymal stem cells through peripheral vein
Other Names:
|
|
Experimental: medium-high-dose stem cell group (3×10^6cells/kg per infusion)
Peripheral intravenous infusion of medium-high-dose stem cells
|
Different dosage of umbilical cord-mesenchymal stem cells through peripheral vein
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Survival rate
Time Frame: 1 year
|
Number of subjects surviving after one year
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in liver function
Time Frame: 1, 4, 8, 12, 24, and 48 weeks
|
The values of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, serum albumin, prothrombin time, and international normalized ratio and the scores of MELD and Child-Pugh
|
1, 4, 8, 12, 24, and 48 weeks
|
|
Incidence of hepatic decompensation events
Time Frame: 1 year
|
Number of patients who developed gastrointestinal bleeding, ascites and hepatic encephalopathy
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mengfan Ruan, MM, The General Hospital of Northern Theater Command
Publications and helpful links
General Publications
- Zhang L, Ma XJ, Fei YY, Han HT, Xu J, Cheng L, Li X. Stem cell therapy in liver regeneration: Focus on mesenchymal stem cells and induced pluripotent stem cells. Pharmacol Ther. 2022 Apr;232:108004. doi: 10.1016/j.pharmthera.2021.108004. Epub 2021 Sep 28.
- Khan S, Khan RS, Newsome PN. Cell Therapy for Liver Disease: From Promise to Reality. Semin Liver Dis. 2020 Nov;40(4):411-426. doi: 10.1055/s-0040-1717096. Epub 2020 Dec 24.
- Alfaifi M, Eom YW, Newsome PN, Baik SK. Mesenchymal stromal cell therapy for liver diseases. J Hepatol. 2018 Jun;68(6):1272-1285. doi: 10.1016/j.jhep.2018.01.030. Epub 2018 Feb 7.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- XHNKKY-DDSC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.